Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that the APL-2302 clinical trial application was approved by the FDA

SZSI · Oct 25

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.